SCHEMBL1070965

SCHEMBL1070965

COC(=O)c1c(Br)ccc([N+](=O)[O-])c1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
MAPT P10636 4/20 0.41
KMT2A Q03164 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP2D6 P10635 2/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.41
ABCC4 O15439 1/20 0.41
PLIN1 O60240 1/20 0.41
CACNA1F O60840 1/20 0.41
GMNN O75496 1/20 0.41
KCNK2 O95069 1/20 0.41
ABCB11 O95342 1/20 0.41
GSR P00390 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19890717 0.84 POLB (0.58) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL5309337 0.84 TSHR (0.44) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL1918262 0.83 SMN1; SMN2 (0.47) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL31452008 0.83 SMN1; SMN2 (0.41) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL18361878 0.83 SMN1; SMN2 (0.51) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL1335324 0.81 KMT2A (0.46) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL5312707 0.81 SMN1; SMN2 (0.39) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL1070849 0.80 TDP1 (0.45) KMT2ATDP1ALDH1A1CYP2D6LMNA
SCHEMBL31285049 0.80 SMN1; SMN2 (0.41) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1
SCHEMBL31284435 0.80 SMN1; SMN2 (0.41) SMN1; SMN2MAPTKMT2ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039895-A1 PROLYL HYDROXYLASE INHIBITORS Glaxo Smith Kline LLC., a corporation 2011-02-17 US disclosed
EP-2273879-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2011-01-19 EP disclosed
WO-2009134850-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039895-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 SMN1; SMN2 3216/4885MAPT 4507/4885KMT2A 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.